Becton, Dickinson and Company logo

Becton, Dickinson and Company (0R19)

Market Closed
3 Jul, 15:30
LSE LSE
$
176. 30
-0.53
-0.3%
$
61.25B Market Cap
- P/E Ratio
3.8% Div Yield
745 Volume
- Eps
$ 176.83
Previous Close
Day Range
176 178.59
Year Range
163.64 251.07
Want to track 0R19 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 29 days

Summary

0R19 closed Thursday lower at $176.3, a decrease of 0.3% from Wednesday's close, completing a monthly increase of 1.91% or $3.3. Over the past 12 months, 0R19 stock lost -22.95%.
0R19 pays dividends to its shareholders, with the most recent payment made on Jun 30, 2025. The next estimated payment will be in In 2 months on Sep 30, 2025 for a total of $1.04.
The last earnings report, released on May 01, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.83%, based on the last three reports. The next scheduled earnings report is due on Aug 07, 2025.
Becton, Dickinson and Company has completed 5 stock splits, with the recent split occurring on Apr 01, 2022.
The company's stock is traded on 15 different exchanges and in various currencies, with the primary listing on NYSE (USD).

0R19 Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment

BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment

FRANKLIN LAKES, N.J. , July 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that, effective July 2, Bilal Muhsin has been named executive vice president and will become the president of BD's future Connected Care segment, as part of the company's previously announced plans to update its structure as it advances its New BD strategy.

Prnewswire | 1 day ago
3 Undervalued Dividend King Stocks With Over 50% Upside Potential

3 Undervalued Dividend King Stocks With Over 50% Upside Potential

As we enter the second half of 2025, now is the perfect time to invest in dividend stocks — especially those with quality underlying fundamentals that pay high dividend yields.

247wallst | 6 days ago
Becton, Dickinson and Company (BDX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Becton, Dickinson and Company (BDX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Becton, Dickinson and Company (NYSE:BDX ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 2:00 PM ET Company Participants Thomas E. Polen - President, CEO & Chairman Conference Call Participants Robert Justin Marcus - JPMorgan Chase & Co, Research Division Unidentified Analyst Yes.

Seekingalpha | 4 weeks ago

Becton, Dickinson and Company Dividends

Becton, Dickinson and Company logo
0R19 4 months ago
Other
$1.04 Per Share
Becton, Dickinson and Company logo
0R19 7 months ago
Other
$1.04 Per Share
Becton, Dickinson and Company logo
0R19 10 months ago
Other
$0.95 Per Share
Becton, Dickinson and Company logo
0R19 10 Jun 2024
Other
$0.95 Per Share
Becton, Dickinson and Company logo
0R19 7 Mar 2024
Other
$0.95 Per Share

Becton, Dickinson and Company Earnings

7 Aug 2025 (In 4 weeks) Date
3.41
Cons. EPS
-
EPS
1 May 2025 Date
-
Cons. EPS
-
EPS
30 Jan 2025 Date
-
Cons. EPS
1.04
EPS
7 Nov 2024 Date
-
Cons. EPS
1.45
EPS
1 Aug 2024 Date
-
Cons. EPS
1.68
EPS
Becton, Dickinson and Company logo
0R19 4 months ago
Other
$1.04 Per Share
Becton, Dickinson and Company logo
0R19 7 months ago
Other
$1.04 Per Share
Becton, Dickinson and Company logo
0R19 10 months ago
Other
$0.95 Per Share
Becton, Dickinson and Company logo
0R19 10 Jun 2024
Other
$0.95 Per Share
Becton, Dickinson and Company logo
0R19 7 Mar 2024
Other
$0.95 Per Share
7 Aug 2025 (In 4 weeks) Date
3.41
Cons. EPS
-
EPS
1 May 2025 Date
-
Cons. EPS
-
EPS
30 Jan 2025 Date
-
Cons. EPS
1.04
EPS
7 Nov 2024 Date
-
Cons. EPS
1.45
EPS
1 Aug 2024 Date
-
Cons. EPS
1.68
EPS

Becton, Dickinson and Company (0R19) FAQ

What is the stock price today?

The current price is $176.30.

On which exchange is it traded?

Becton, Dickinson and Company is listed on NYSE.

What is its stock symbol?

The ticker symbol is 0R19.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 3.8%.

What is its market cap?

As of today, the market cap is 61.25B.

What is the earnings per share?

The EPS is 3.41.

When is the next earnings date?

The next earnings report will release on Aug 07, 2025.

Has Becton, Dickinson and Company ever had a stock split?

Becton, Dickinson and Company had 5 splits and the recent split was on Apr 01, 2022.

Becton, Dickinson and Company Profile

Medical - Instruments & Supplies Industry
Healthcare Sector
Thomas E. Polen Jr. CEO
LSE Exchange
US0758871091 ISIN
US Country
70,000 Employees
10 Mar 2025 Last Dividend
1 Apr 2022 Last Split
- IPO Date

Overview

Becton, Dickinson and Company, commonly known as BD, is a global leader in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. Catering to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public, BD operates worldwide. The company’s extensive product portfolio is strategically segmented into three core areas: BD Medical, BD Life Sciences, and BD Interventional. Founded in 1897, BD has established a robust presence in the healthcare sector, headquartered in Franklin Lakes, New Jersey.

Products and Services

  • BD Medical:

    This segment provides a comprehensive range of products, including peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, and vascular access technology. It also offers vascular care, preparation products, needle-free IV connectors, closed-system drug transfer devices, hazardous drug detections, and a variety of syringes and needles. For drug delivery and safety, it covers IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, as well as automated medication dispensing and supply management systems, enhancing medication inventory optimization and tracking. Additionally, BD Medical produces prefillable drug delivery systems.

  • BD Life Sciences:

    In this area, BD presents an array of solutions for specimen and blood collection and an extensive selection of diagnostic tools, including automated culturing for blood and tuberculosis, molecular testing systems, products for microorganism identification, and drug susceptibility testing. The segment also specializes in liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media products. For cellular analysis, it offers fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, crucial for clinical oncology, immunological research, and transplantation diagnostics or monitoring.

  • BD Interventional:

    BD's interventional segment covers a wide range of surgical and medical products, including those for hernia and soft tissue repair, biosurgery, and surgical infection prevention. It also offers biological and bioresorbable grafts, peripheral intervention products, and equipment for urology and critical care. These products are designed to improve patient outcomes and support the efficiency of medical procedures.

Contact Information

Address: 1 Becton Drive
Phone: 201 847 6800